CHF20.40
0.49%
SIX Swiss Exchange, Thu, Apr 17 2025
ISIN
CH0042615283
Symbol
DOCM

DocMorris Target price 2025 - Analyst rating & recommendation

DocMorris Classifications & Recommendation:

Buy
27%
Hold
64%
Sell
9%

DocMorris Price Target

Target Price CHF32.60
Price CHF20.40
Potential
Number of Estimates 10
10 Analysts have issued a price target DocMorris 2026 . The average DocMorris target price is CHF32.60. This is higher than the current stock price. The highest price target is
CHF60.00 194.12%
register free of charge
, the lowest is .
A rating was issued by 11 analysts: 3 Analysts recommend DocMorris to buy, 7 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the DocMorris stock has an average upside potential 2026 of . Most analysts recommend the DocMorris stock at Hold.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion CHF 1.02 1.18
4.91% 16.30%
EBITDA Margin -4.52% -2.80%
35.16% 38.01%
Net Margin -9.59% -6.87%
19.26% 28.35%

12 Analysts have issued a sales forecast DocMorris 2025 . The average DocMorris sales estimate is

CHF1.2b
Unlock
. This is
16.30% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF1.3b 30.12%
Unlock
, the lowest is
CHF1.1b 10.91%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF1.0b 4.91%
2025
CHF1.2b 16.30%
Unlock
2026
CHF1.4b 20.07%
Unlock
2027
CHF1.6b 15.35%
Unlock
2028
CHF1.7b 3.52%
Unlock

12 Analysts have issued an DocMorris EBITDA forecast 2025. The average DocMorris EBITDA estimate is

CHF-33.1m
Unlock
. This is
24.42% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF-19.9m 54.62%
Unlock
, the lowest is
CHF-50.8m 15.85%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF-45.9m 41.79%
2025
CHF-33.1m 27.86%
Unlock
2026
CHF-1.1m 96.80%
Unlock
2027
CHF29.4m 2,871.47%
Unlock
2028
CHF57.9m 96.69%
Unlock

EBITDA Margin

2024 -4.52% 35.16%
2025
-2.80% 38.01%
Unlock
2026
-0.07% 97.50%
Unlock
2027
1.80% 2,671.43%
Unlock
2028
3.41% 89.44%
Unlock

9 DocMorris Analysts have issued a net profit forecast 2025. The average DocMorris net profit estimate is

CHF-81.3m
Unlock
. This is
16.54% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF-57.1m 41.38%
Unlock
, the lowest is
CHF-116m 19.54%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF-97.5m 15.30%
2025
CHF-81.3m 16.64%
Unlock
2026
CHF-56.0m 31.12%
Unlock
2027
CHF-30.5m 45.56%
Unlock
2028
CHF-12.4m 59.25%
Unlock

Net Margin

2024 -9.59% 19.26%
2025
-6.87% 28.35%
Unlock
2026
-3.94% 42.65%
Unlock
2027
-1.86% 52.79%
Unlock
2028
-0.73% 60.75%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF -8.25 -6.88
15.30% 16.61%
P/E negative
EV/Sales 0.39

9 Analysts have issued a DocMorris forecast for earnings per share. The average DocMorris EPS is

CHF-6.88
Unlock
. This is
16.50% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF-4.83 41.38%
Unlock
, the lowest is
CHF-9.85 19.54%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF-8.25 15.30%
2025
CHF-6.88 16.61%
Unlock
2026
CHF-4.74 31.10%
Unlock
2027
CHF-2.58 45.57%
Unlock
2028
CHF-1.05 59.30%
Unlock

P/E ratio

Current -2.48 71.88%
2025
-2.97 19.76%
Unlock
2026
-4.31 45.12%
Unlock
2027
-7.91 83.53%
Unlock
2028
-19.42 145.51%
Unlock

Based on analysts' sales estimates for 2025, the DocMorris stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.45 64.57%
2025
0.39 13.98%
Unlock
2026
0.32 16.71%
Unlock
2027
0.28 13.31%
Unlock
2028
0.27 3.40%
Unlock

P/S ratio

Current 0.24 77.15%
2025
0.20 14.01%
Unlock
2026
0.17 16.73%
Unlock
2027
0.15 13.26%
Unlock
2028
0.14 3.40%
Unlock

Current DocMorris Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
STIFEL EUROPE
Locked
Locked
Locked Apr 03 2025
JEFFERIES
Locked
Locked
Locked Apr 02 2025
BERENBERG
Locked
Locked
Locked Mar 31 2025
HSBC
Locked
Locked
Locked Mar 23 2025
RESEARCH PARTNERS AG
Locked
Locked
Locked Mar 16 2025
WARBURG RESEARCH GMBH
Locked
Locked
Locked Mar 12 2025
BAADER HELVEA EQUITY RESEARCH
Locked
Locked
Locked Mar 12 2025
Analyst Rating Date
Locked
STIFEL EUROPE:
Locked
Locked
Apr 03 2025
Locked
JEFFERIES:
Locked
Locked
Apr 02 2025
Locked
BERENBERG:
Locked
Locked
Mar 31 2025
Locked
HSBC:
Locked
Locked
Mar 23 2025
Locked
RESEARCH PARTNERS AG:
Locked
Locked
Mar 16 2025
Locked
WARBURG RESEARCH GMBH:
Locked
Locked
Mar 12 2025
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
Locked
Mar 12 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today